NCT03829618

Brief Summary

The purpose of this study is to assess if there is decrease in cough during flexible bronchoscopy and endobronchial ultrasound when different modes of lidocaine administration are used. The modes of administration being evaluated are topical, nebulized and atomized.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
29

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Apr 2019

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 24, 2019

Completed
11 days until next milestone

First Posted

Study publicly available on registry

February 4, 2019

Completed
2 months until next milestone

Study Start

First participant enrolled

April 1, 2019

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2020

Completed
1.1 years until next milestone

Results Posted

Study results publicly available

October 12, 2021

Completed
Last Updated

October 12, 2021

Status Verified

September 1, 2021

Enrollment Period

1.4 years

First QC Date

January 24, 2019

Results QC Date

September 8, 2021

Last Update Submit

October 8, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Cough

    Number of coughs during procedure as defined by cough requiring stopping procedure or treatment by anesthesiologist with propofol or alfentanyl

    1 day

Secondary Outcomes (6)

  • Number of Participants With Post-procedure Sore Throat

    1 day

  • Number of Participants With Post-Procedure Subjective Cough

    1 day

  • Anesthesia Time to Wake up

    1 day

  • Alfentanyl Dosing

    1 day

  • Propofol Dosing

    1 day

  • +1 more secondary outcomes

Study Arms (3)

Topical Lidocaine

ACTIVE COMPARATOR

16 ml of 1% lidocaine sprayed in 4 ml aliquots to vocal cords, midtrachea, left main stem bronchus and right main stem bronchus.

Drug: Topical lidocaine

Nebuliser Solution

ACTIVE COMPARATOR

2% lidocaine dosed at 2mg/kg with max dose of 160mg nebulized via jet nebulizer in operating room over ten minutes.

Drug: Nebuliser solution

Nebuliser Suspension

ACTIVE COMPARATOR

2% lidocaine dosed at 2mg/kg with max dose of 160mg nebulized via vibrating mesh nebulizer in operating room over ten minutes.

Drug: Nebuliser Suspension

Interventions

1% lidocaine topically applied in 4 mL aliquots

Also known as: Topical
Topical Lidocaine

2% lidocaine dose at 2 mg/kg (max 160 mg) applied via jet nebulizer

Also known as: Nebulizer
Nebuliser Solution

2% lidocaine dosed at 2 mg/kg (max 160 mg) applied via vibrating mesh nebulizer

Also known as: Atomizer
Nebuliser Suspension

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of mediastinal and/or hilar lymphadenopathy requiring endobronchial ultrasound evaluation and transbronchial needle aspiration.
  • Diagnosis of pulmonary disease requiring flexible bronchoscopy
  • Greater than 18 years of age.

You may not qualify if:

  • Any intervention beyond flexible bronchoscopy and endobronchial ultrasound
  • Inability to tolerate bronchoscopy.
  • Patients that receive paralytics.
  • Patients with neuromuscular diseases.
  • Inability to consent for procedures.
  • Allergies to lidocaine or any other drugs used in protocol.
  • Existing renal insufficiency or liver disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Penn State Hershey Medical Center

Hershey, Pennsylvania, 17036, United States

Location

Related Publications (5)

  • Madan K, Biswal SK, Mittal S, Hadda V, Mohan A, Khilnani GC, Pandey RM, Guleria R. 1% Versus 2% Lignocaine for Airway Anesthesia in Flexible Bronchoscopy Without Lignocaine Nebulization (LIFE): A Randomized Controlled Trial. J Bronchology Interv Pulmonol. 2018 Apr;25(2):103-110. doi: 10.1097/LBR.0000000000000458.

    PMID: 29346249BACKGROUND
  • Stolz D, Chhajed PN, Leuppi J, Pflimlin E, Tamm M. Nebulized lidocaine for flexible bronchoscopy: a randomized, double-blind, placebo-controlled trial. Chest. 2005 Sep;128(3):1756-60. doi: 10.1378/chest.128.3.1756.

    PMID: 16162784BACKGROUND
  • Wahidi MM, Jain P, Jantz M, Lee P, Mackensen GB, Barbour SY, Lamb C, Silvestri GA. American College of Chest Physicians consensus statement on the use of topical anesthesia, analgesia, and sedation during flexible bronchoscopy in adult patients. Chest. 2011 Nov;140(5):1342-1350. doi: 10.1378/chest.10-3361.

    PMID: 22045879BACKGROUND
  • Dreher M, Cornelissen CG, Reddemann MA, Muller A, Hubel C, Muller T. Nebulized versus Standard Local Application of Lidocaine during Flexible Bronchoscopy: A Randomized Controlled Trial. Respiration. 2016;92(4):266-273. doi: 10.1159/000449135. Epub 2016 Sep 10.

    PMID: 27614989BACKGROUND
  • Amini S, Peiman S, Khatuni M, Ghalamkari M, Rahimi B. The Effect of Dextromethorphan Premedication on Cough and Patient Tolerance During Flexible Bronchoscopy: A Randomized, Double-blind, Placebo-controlled Trial. J Bronchology Interv Pulmonol. 2017 Oct;24(4):263-267. doi: 10.1097/LBR.0000000000000385.

MeSH Terms

Conditions

PneumoniaLung Neoplasms

Interventions

LidocaineNebulizers and Vaporizers

Condition Hierarchy (Ancestors)

Respiratory Tract InfectionsInfectionsLung DiseasesRespiratory Tract DiseasesRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasms

Intervention Hierarchy (Ancestors)

AcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAminesEquipment and Supplies

Limitations and Caveats

The target enrollment was not reached secondary to the COVID-19 pandemic.

Results Point of Contact

Title
Zoulfira Nisnevitch-Savarese, M.D.
Organization
Penn State Hershey Medical Center

Study Officials

  • Jennifer Toth

    Milton S. Hershey Medical Center

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Medicine and Surgery, Director of Interventional Pulmonology

Study Record Dates

First Submitted

January 24, 2019

First Posted

February 4, 2019

Study Start

April 1, 2019

Primary Completion

August 31, 2020

Study Completion

August 31, 2020

Last Updated

October 12, 2021

Results First Posted

October 12, 2021

Record last verified: 2021-09

Data Sharing

IPD Sharing
Will not share

Locations